Please use this identifier to cite or link to this item:
|Title:||Optimal antiplatelet treatment for percutaneous coronary intervention: Clopidogrel vs. ticlopidine|
|Authors:||Almsherqi, Z.A. |
Percutaneous coronary intervention
|Citation:||Almsherqi, Z.A., McLachlan, C.S., Mossop, P., Deng, Y. (2007-01-02). Optimal antiplatelet treatment for percutaneous coronary intervention: Clopidogrel vs. ticlopidine. International Journal of Cardiology 114 (1) : 101-102. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ijcard.2005.09.052|
|Abstract:||Antiplatelet treatment for patients undergoing percutaneous coronary interventions is a rapidly changing area. Thienopyridines derivatives (ticlopidine and clopidogrel) have shown to decrease major cardiovascular events. Ticlopidine can cause rare but serious side effects, especially during the first 3 months of treatment. Clopidogrel appears to be a safer alternative to ticlopidine. However, resistance to clopidogrel therapy may increases the risk of recurrent cardiovascular events. Whether increased doses of clopidogrel might overcome this resistance in nonresponsive patients warrants further investigation. © 2005 Elsevier Ireland Ltd. All rights reserved.|
|Source Title:||International Journal of Cardiology|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jul 10, 2018
WEB OF SCIENCETM
checked on May 30, 2018
checked on Jul 12, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.